<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71227</article-id><article-id pub-id-type="doi">10.26442/00403660.2021.04.200812</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Peculiarities of Mild Asthma in Russia: the Results of SYGMA2 Study</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности легкой бронхиальной астмы в России: результаты исследования SYGMA2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4044-674X</contrib-id><name-alternatives><name xml:lang="en"><surname>Aisanov</surname><given-names>Zaurbek R.</given-names></name><name xml:lang="ru"><surname>Айсанов</surname><given-names>Заурбек Рамазанович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф. каф. пульмонологии</p></bio><email>aisanov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5999-2150</contrib-id><name-alternatives><name xml:lang="en"><surname>Avdeev</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Авдеев</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>чл.-кор. РАН, д.м.н., проф., зав. каф. пульмонологии</p></bio><email>aisanov@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5671-3478</contrib-id><name-alternatives><name xml:lang="en"><surname>Arkhipov</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>Архипов</surname><given-names>Владимир Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф. каф. клинической фармакологии и терапии</p></bio><email>aisanov@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6050-724X</contrib-id><name-alternatives><name xml:lang="en"><surname>Belevsky</surname><given-names>Andrey S.</given-names></name><name xml:lang="ru"><surname>Белевский</surname><given-names>Андрей Станиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф., зав. каф. пульмонологии</p></bio><email>aisanov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8216-417X</contrib-id><name-alternatives><name xml:lang="en"><surname>Voznesenskiy</surname><given-names>Nikolay A.</given-names></name><name xml:lang="ru"><surname>Вознесенский</surname><given-names>Николай Арнольдович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., вед. инженер</p></bio><email>aisanov@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России&#13;
(Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Severtsov Institute of Ecology and Evolution</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт проблем экологии и эволюции им. А.Н. Северцова» РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2021</year></pub-date><volume>93</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>449</fpage><lpage>455</lpage><history><date date-type="received" iso-8601-date="2021-06-02"><day>02</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-02"><day>02</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/71227">https://ter-arkhiv.ru/0040-3660/article/view/71227</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>Patients with mild asthma may experience severe exacerbations. This analysis was conducted to investigate regional peculiarities of mild asthma population in Russia.</p> <p><bold>Materials and methods. </bold>The SYGMA2 is a double-blind multinational study involving adult patients with mild asthma (<italic>n</italic>=4176). We conducted an open-label descriptive analysis of the baseline characteristics of the Russian group (<italic>n</italic>=579) of SYGMA2 trial comparing to SYGMA2 population from other countries. The subanalysis was descriptive only, and no hypothesis were tested.</p> <p><bold>Results. </bold>The Russian population of patients with mild asthma was comparable to the rest of countries in terms of demographic characteristics, smoking status and duration of asthma. The spirometric parameters in the Russian group was slightly worse than in the other population. At the study entry 48% of Russian patients had symptom control on maintenance therapy, but 52% were uncontrolled on short-acting bronchodilators. While in other countries this ratio was inverse (55/45%). More patients with mild asthma in the Russian group had at least one severe exacerbation in the previous year (30.1% vs 20.7% in other countries).</p> <p><bold>Conclusion. </bold>We revealed a delayed prescription of controller therapy and overuse of short-acting bronchodilators in the Russian group of mild asthma patients, that may increase risk of asthma non-control and severe exacerbation.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Региональные особенности легкой бронхиальной астмы (БА) в целом изучены недостаточно. Данный ретроспективный анализ проводился для изучения региональных особенностей российской популяции пациентов с легкой БА, в том числе статуса контроля, фармакотерапии и частоты тяжелых обострений.</p> <p><bold>Материалы и методы. </bold>Исследование SYGMA2 – двойное слепое международное исследование у взрослых пациентов с легкой БА (<italic>n</italic>=4176). Нами проведен открытый ретроспективный анализ исходных характеристик российской группы исследования SYGMA2 (<italic>n</italic>=579) по сравнению с пациентами из других стран. Данный анализ был описательным по своей сути и не тестировал каких-либо гипотез.</p> <p><bold>Результаты. </bold>Российская группа практически не отличалась от популяции остальных стран по демографическим параметрам, статусу курения и длительности заболевания. Показатели спирометрии в российской группе оказались несколько хуже, чем у пациентов из других стран. При включении в исследование 48% пациентов из России получали регулярное базисное лечение и имели контроль БА, а 52% использовали только короткодействующие бронходилататоры и не достигали контроля БА. В остальной популяции распределение было обратным – 55/45%. В России также была больше доля пациентов, перенесших хотя бы 1 тяжелое обострение БА за предшествующий год (30,1%), по сравнению с 20,7% в других странах.</p> <p><bold>Заключение. </bold>У пациентов с легкой БА в России наблюдается более позднее назначение базисной терапии и избыточное применение короткодействующих бронходилататоров. Это может приводить к недостаточному контролю симптомов и повышать риск тяжелых обострений БА.</p></trans-abstract><kwd-group xml:lang="en"><kwd>asthma</kwd><kwd>mild asthma</kwd><kwd>maintenance therapy</kwd><kwd>symptom control</kwd><kwd>severe exacerbation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бронхиальная астма</kwd><kwd>легкая бронхиальная астма</kwd><kwd>базисная терапия</kwd><kwd>контроль астмы</kwd><kwd>тяжелое обострение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>2019 GINA Main Report – Global Initiative for Asthma – GINA. Available at: https://ginasthma.org/gina-reports. Accessed: 08.03.2021.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Dusser D, Montani D, Chanez P, et al. Mild asthma: An expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591-604. doi: 10.1111/j.1398-9995.2007.01394.x</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: The global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40-7. doi: 10.1016/j.jaci.2004.04.042</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zureik M, Neukirch C, Leynaert B, et al. Sensitisation to airborne moulds and severity of asthma: Cross sectional study from European Community respiratory health survey. Br Med J. 2002;325(7361):411-4. doi: 10.1136/bmj.325.7361.411</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Liard R, Leynaert B, Zureik M, et al. Using Global Initiative for Asthma guidelines to assess asthma severity in populations. Eur Respir J. 2000;16(4):615-20. doi: 10.1034/j.1399-3003.2000.16d08.x</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Com-Ruelle L, Crestin B, Dumesnil S. L’asthme En France Selon Les Stades de Sévérité, 2000. Available at: https://www.researchgate.net/publication/268413581. Accessed: 08.06.2020.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bloom CI, Nissen F, Douglas IJ, et al. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax. 2018;73(4):313-20. doi: 10.1136/thoraxjnl-2017-210650</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011;6:87-93 [Arkhipov VV, Grigoryeva EV, Gavrishina EV. Control of bronchial asthma in Russia: results of NIKA multi-center observational study. Pulmonologiya. 2011;6:87-93 (In Russ.)]. doi: 10.18093/0869-0189-2011-0-6-87-93</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1). doi: 10.1186/s12890-017-0409-3</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wells KE, Peterson EL, Ahmedani BK, et al. The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol. 2012;129(5):1274. doi: 10.1016/j.jaci.2011.12.974</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: Current status and future perspectives. Respir Care. 2015;60(3):455-68. doi: 10.4187/respcare.03200</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880-4. doi: 10.1136/thorax.57.10.880</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332-6. doi: 10.1056/NEJM200008033430504</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>O’Byrne PM, FitzGerald JM, Zhong N, et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given “as needed” in mild asthma: Study protocols for two randomised controlled trials. Trials. 2017;18(1). doi: 10.1186/s13063-016-1731-4</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lipworth B, Chan R, Chris, Kuo R. Anti-inflammatory reliever therapy for asthma. Ann Allergy Asthma Immunol. 2020;124:13-5. doi: 10.1016/j.anai.2019.10.002</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537): 744-53. doi: 10.1016/S0140-6736(06)69284-2</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129-36. doi: 10.1164/rccm.200407-884OC</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial. Lancet Respir Med. 2013;1(1):32-42. doi: 10.1016/S2213-2600(13)70007-9</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Beasley R, Weatherall M, Shirtcliffe P, et al. Combination corticosteroid/β-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014;133(1):39-41. doi: 10.1016/j.jaci.2013.10.053</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J. 2006;28(4):748-55. doi: 10.1183/09031936.06.00128005</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018;378(20):1865-76. doi: 10.1056/NEJMoa1715274</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018;378(20):1877-87. doi: 10.1056/NEJMoa1715275</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-43. doi: 10.1183/09031936.00080312</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Cooper BG, Stocks J, Hall GL, et al. The global lung function initiative (GLI) network: Bringing the world’s respiratory reference values together. Breathe. 2017;13(3):e56-e64. doi: 10.1183/20734735.012717</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4). doi: 10.1183/13993003.01872-2019</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Janson C, Menzies-Gow A, Nan C, et al. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Adv Ther. 2020;37(3):1124-35. doi: 10.1007/s12325-020-01233-0</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Muneswarao J, Hassali MA, Ibrahim B, et al. It is time to change the way we manage mild asthma: An update in GINA 2019. Respir Res. 2019;20(1). doi: 10.1186/s12931-019-1159-y</mixed-citation></ref></ref-list></back></article>
